2,549
Participants
Start Date
January 1, 2025
Primary Completion Date
December 31, 2028
Study Completion Date
December 31, 2028
MRI contrast-enhancing agents
All patients underwent standard pelvic MRI examinations (1.5T or 3T) with the following sequences: T2-weighted imaging (T2WI), T1-weighted imaging (T1WI) with and without fat suppression; axial, sagittal, and coronal post-contrast T1WI following intravenous administration of gadolinium-based contrast agents (GBCA); functional sequences including dynamic contrast-enhanced MRI (DCE-MRI) and diffusion-weighted imaging MRI (DWI-MRI). Enhancement sequences may be omitted if no adnexal masses were identified on T2WI, T1WI, or DWI sequences.
Zhongshan Hospital, Fudan University, Shanghai
Shanghai Gynecologic Oncology Group
OTHER_GOV